Houston cell therapy company launches second-phase clinical trial

fighting cancer

March Biosciences is testing its MB-105 cell therapy in a Phase 2 clinical trial for people with difficult-to-treat cancer. Photo via march.bio

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.

From Your Site Articles
Early-stage cell therapy startup March Biosciences has partnered with CTMC. Photo via march.bio

Cancer-fighting startup partners with Houston cell therapy accelerator

marching on

When it came time to name their cell therapy startup, Houston life science innovators simply had to look to their calendar.

“I would argue that March is the best month in Houston,” Sarah Hein tells InnovationMap. “We started talking about putting this company together during COVID, so we were outside a lot. And we actually got together in March.”

That’s why the CEO and her co-founders Max Mamonkin and Malcolm Brenner decided to name their company March Biosciences.

It's a fresh, unstuffy name for a startup that has an innovative take on cancer immunotherapy. Their lead asset is an advanced cellular therapy known as MB-105, an autologous CD5 CAR T cell therapy. For patients with T-cell lymphoma and leukemia who have failed all currently available lines of therapy, the prognosis is understandably extremely poor. But in a phase one study, MB-105 has been proven to safely treat those patients. The phase two study is expected to begin in the first half of 2024.

Hein met Mamonkin at the TMC Accelerator for Cancer Therapeutics (ACT), at which the alumna of Resonant Therapeutics and Courier Therapeutics was an entrepreneur in residence.

“It's a perfect example of the opportunities here in Houston where you can go from bench to bedside, essentially, in the same institution. And Baylor has been particularly good at that because of the Center for Cell and Gene Therapy,” says Hein.

The serial entrepreneur first came to Houston as a PhD student in molecular and cellular biology at Baylor College of Medicine, but during her studies she became excited by the startup ecosystem in her new hometown. After earning her degree, she became a venture fellow at the Mercury Fund. Her experience in both science and business made her an ideal candidate to take March Biosciences to the next level.

In September, the company announced that it formed a strategic alliance with CTMC (Cell Therapy Manufacturing Center), a joint venture between MD Anderson Cancer Center and National Resilience.

“Our unique risk-sharing model allows us to collaborate with organizations like March Biosciences to accelerate the development and manufacture of innovative cell therapies, like MB-105, and bring them into the clinic with a consistent and scalable manufacturing process,” said CTMC’s CEO, Jason Bock in a press release.

The partnership “has allowed us to move really quickly,” Hein says.

That’s because what CTMC does uniquely well is take early stage companies like March Biosciences and advance them to a state that’s ready for manufacturing in a short time, around 18 months, says Hein.

According to Hein, March Biosciences’ success is a testament to Houston and its world-class medical center.

“It’s a great example of the opportunities you see here in Houston, where we have a technology that was developed by brilliant scientists here in Houston and we can pull together the resources that we need to take it to the next level,” Hein says. "Working with partners here in Houston, we have all the pieces and the community rises to the occasion to support you.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

These 50+ Houston scientists rank among world’s most cited

science stars

Fifty-one scientists and professors from Houston-area universities and institutions were named among the most cited in the world for their research in medicine, materials sciences and an array of other fields.

The Clarivate Highly Cited Researchers considers researchers who have authored multiple "Highly Cited Papers" that rank in the top 1percent by citations for their fields in the Web of Science Core Collection. The final list is then determined by other quantitative and qualitative measures by Clarivate's judges to recognize "researchers whose exceptional and community-wide contributions shape the future of science, technology and academia globally."

This year, 6,868 individual researchers from 60 different countries were named to the list. About 38 percent of the researchers are based in the U.S., with China following in second place at about 20 percent.

However, the Chinese Academy of Sciences brought in the most entries, with 258 researchers recognized. Harvard University with 170 researchers and Stanford University with 141 rounded out the top 3.

Looking more locally, the University of Texas at Austin landed among the top 50 institutions for the first time this year, tying for 46th place with the Mayo Clinic and University of Minnesota Twin Cities, each with 27 researchers recognized.

Houston once again had a strong showing on the list, with MD Anderson leading the pack. Below is a list of the Houston-area highly cited researchers and their fields.

UT MD Anderson Cancer Center

  • Ajani Jaffer (Cross-Field)
  • James P. Allison (Cross-Field)
  • Maria E. Cabanillas (Cross-Field)
  • Boyi Gan (Molecular Biology and Genetics)
  • Maura L. Gillison (Cross-Field)
  • David Hong (Cross-Field)
  • Scott E. Kopetz (Clinical Medicine)
  • Pranavi Koppula (Cross-Field)
  • Guang Lei (Cross-Field)
  • Sattva S. Neelapu (Cross-Field)
  • Padmanee Sharma (Molecular Biology and Genetics)
  • Vivek Subbiah (Clinical Medicine)
  • Jennifer A. Wargo (Molecular Biology and Genetics)
  • William G. Wierda (Clinical Medicine)
  • Ignacio I. Wistuba (Clinical Medicine)
  • Yilei Zhang (Cross-Field)
  • Li Zhuang (Cross-Field)

Rice University

  • Pulickel M. Ajayan (Materials Science)
  • Pedro J. J. Alvarez (Environment and Ecology)
  • Neva C. Durand (Cross-Field)
  • Menachem Elimelech (Chemistry and Environment and Ecology)
  • Zhiwei Fang (Cross-Field)
  • Naomi J. Halas (Cross-Field)
  • Jun Lou (Materials Science)
  • Aditya D. Mohite (Cross-Field)
  • Peter Nordlander (Cross-Field)
  • Andreas S. Tolias (Cross-Field)
  • James M. Tour (Cross-Field)
  • Robert Vajtai (Cross-Field)
  • Haotian Wang (Chemistry and Materials Science)
  • Zhen-Yu Wu (Cross-Field)

Baylor College of Medicine

  • Nadim J. Ajami (Cross-Field)
  • Biykem Bozkurt (Clinical Medicine)
  • Hashem B. El-Serag (Clinical Medicine)
  • Matthew J. Ellis (Cross-Field)
  • Richard A. Gibbs (Cross-Field)
  • Peter H. Jones (Pharmacology and Toxicology)
  • Sanjay J. Mathew (Cross-Field)
  • Joseph F. Petrosino (Cross-Field)
  • Fritz J. Sedlazeck (Biology and Biochemistry)
  • James Versalovic (Cross-Field)

University of Houston

  • Zhifeng Ren (Cross-Field)
  • Yan Yao (Cross-Field)
  • Yufeng Zhao (Cross-Field)
  • UT Health Science Center Houston
  • Hongfang Liu (Cross-Field)
  • Louise D. McCullough (Cross-Field)
  • Claudio Soto (Cross-Field)

UTMB Galveston

  • Erez Lieberman Aiden (Cross-Field)
  • Pei-Yong Shi (Cross-Field)

Houston Methodist

  • Eamonn M. M. Quigley (Cross-Field)

New report shows surge in startup activity in Houston and across Texas

by the numbers

Houston and the rest of Texas are experiencing a boom in the creation of startups.

One barometer of growth in startup activity: The Houston metro area saw a 92 percent rise from 2024 to 2025 in the number of account applications submitted to Bluevine, a banking platform for small businesses.

New data from Bluevine also shows healthy year-over-year growth in account applications submitted by entrepreneurs in Texas’ three other major metros:

  • 242 percent growth in the San Antonio area
  • 153 percent growth in the Austin area
  • 28 percent growth in Dallas-Fort Worth

Further evidence of Texas’ uptick in business creation comes from a new state-by-state analysis of U.S. Census Bureau data by digital mailbox provider iPostal1.

From 2019 to 2024, the number of new business applications jumped 60 percent in Texas, according to the iPostal1 analysis. Wyoming tops the list, with a five-year growth rate of 216 percent.

“The U.S. has no shortage of ambition, but opportunity isn’t spread evenly,” says Jeff Milgram, founder and CEO of iPostal1. “In states like New York, Florida, and Texas, entrepreneurship is booming — people are starting businesses, taking risks, and finding opportunity.”

“Other states are still catching up,” Milgram adds. “Sometimes it’s access to funding, sometimes local policy, or just the confidence that new ventures will be supported.”

Women own many of the new businesses sprouting in Texas, according to a new analysis of 2024-25 data from the U.S. Small Business Administration. The analysis, done by SimpleTiger, a marketing agency for software-as-a-service (SaaS), shows Texas ranks eighth for the highest concentration of women entrepreneurs (109 per 1,000 female residents) among all states. That rate is three percent higher than the national average.

“Women entrepreneurs are no longer a side story in small business growth; they’re a leading indicator of where local economies are expanding next,” SimplyTiger says. “When women-owned business density is high, it usually signals stronger access to customers, networks, and startup pathways that make it easier to launch and keep going.”

In a December news release, Gov. Greg Abbott highlights Texas’ nation-leading job gains over the past 12 months, driven by employers small and large.

“From innovative startups to Fortune 500 corporations, job-creating businesses invest with confidence in Texas,” Abbott says. “With our strong and growing workforce, we will continue to expand career and technical training programs for better jobs and bigger paycheck opportunities for more Texans.”

Houston poised to add 30,900 new jobs in 2026, forecast says

jobs forecast

Buoyed by the growing health care sector, the Houston metro area will add 30,900 jobs in 2026, according to a new forecast from the Greater Houston Partnership.

The report predicts the Houston area’s health care sector will tack on 14,000 jobs next year, which would make it the No. 1 industry for local job growth. The 14,000 health care jobs would represent 45 percent of the projected 30,900 new jobs. In the job-creation column, the health care industry is followed by:

  • Construction: addition of 6,100 jobs in 2026
  • Public education: Addition of 5,800 jobs
  • Public administration: Addition of 5,000 jobs

At the opposite end of the regional workforce, the administrative support services sector is expected to lose 7,500 jobs in 2026, preceded by:

  • Manufacturing: Loss of 3,400 jobs
  • Oil-and-gas extraction: Loss of 3,200 jobs
  • Retail: Loss of 1,800 jobs

“While current employment growth has moderated, the outlook remains robust and Houston’s broader economic foundation remains strong,” GHP president and CEO Steve Kean said in the report.

“Global companies are choosing to invest in Houston — Eli Lilly, Foxconn, Inventec, and others — because they believe in our workforce and our long-term trajectory,” Kean added. “These commitments reinforce that Houston is a place where companies can scale and where our economy continues to demonstrate its resilience as a major engine for growth and opportunity. These commitments and current prospects we are working on give us confidence in the future growth of our economy.”

The Greater Houston Partnership says that while the 30,900-job forecast falls short of the region’s recent average of roughly 50,000 new jobs per year, it’s “broadly in line with the muted national outlook” for employment gains anticipated in 2026.

“Even so, Houston’s young, skilled workforce and strong pipeline of major new projects should help offset energy sector pressures and keep regional growth on pace with the nation,” the report adds.

The report says that even though the health care sector faces rising insurance costs, which might cause some people to delay or skip medical appointments, and federal changes in Medicare and Medicaid, strong demographic trends in the region will ensure health care remains “a key pillar of Houston’s economy.”

As for the local oil-and-gas extraction industry, the report says fluctuations and uncertainty in the global oil-and-gas market will weigh on the Houston sector in 2026. Furthermore, oil-and-gas layoffs partly “reflect a longer-term trend as companies in the sector move toward greater efficiency using fewer workers to produce similar volumes,” according to the report.

View All Listings